Skip to main content
Equibles
TMCI logo

TMCI · Treace Medical Concepts, Inc. · Documents

Track TMCI — free

Use TMCI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMCI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.03 -0.15 (-3.59%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$264.21M
Shares
65.56M
Volume · Nov 6 596.72K Avg daily vol (3M) 274.2K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $212.69M up 1.6% 10-K filed Feb 27, 2026 Quarterly report New FY2026 Q3 Revenue $48.25M down 3.9% 10-Q filed Nov 6, 2026 Latest results New Revenue falls as 2026 loss outlook improves 8-K filed Nov 6, 2026 Earnings call Q2 2026 earnings call Held Aug 7, 2026
2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $48.25M ▼ 3.9% Net loss $12.57M Diluted EPS -$0.19
Nov 6
Current report 8-K
Revenue falls as 2026 loss outlook improves

Treace Medical Concepts updated full-year 2026 revenue guidance to $206 million to $210 million and expects an Adjusted EBITDA loss of $1.0 million to $2.0 million, after third-quarter revenue declined 4% to $48.3 million.

Financial results
3 source passages
Revenue for the third quarter of 2026 was $48.3 million, representing a decrease of 4% compared to $50.2 million in the third quarter of 2025. The Company is updating its full-year 2026 revenue guidance to be in the range of $206 million to $210 million, from the prior range of $204 million to $212 million, representing a decline of 3% to 1% compared to full-year 2025. The Company is updating its expectation of a loss in Adjusted EBITDA to be in the range of $1.0 million to $2.0 million for full year 2026, from the prior range of $3.0 million to $5.0 million for full year 2026. Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $45.38M ▼ 4.2% Net loss $15.87M Diluted EPS -$0.24
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $47.2M ▼ 10.2% Net loss $17.96M Diluted EPS -$0.28
Feb 27
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $212.69M ▲ 1.6% Net loss $59M Diluted EPS -$0.93
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $209.36M ▲ 11.9% Net loss $55.74M Diluted EPS -$0.90
2024
Showing 1–50 of 110 documents
Key facts CIK 1630627 CUSIP 89455T109 13F (30d) 55 filings 43 filers Visit website Investor relations